roche glp 1 drug GLP-1 produces “robust” weight loss in late-stage obesity trial | News Roche Enters the GLP-1 Obesity
Description
Formulated to Support GLP-1 Pathways: GLP-1 is a natural hormone in the body associated with wellness
In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide
Perfect for weight management goals
I actually lost weight and feel so much better
Set aside 60 minutes this weekend
This analysis estimates the number of Medicare Part D enrollees who could potentially qualify for the Bridge program by meeting all of the eligibility criteria, based on claims data from 2023.
